Abstract:
PURPOSE: A composition containing neohesperidin dihydrochalcone generally used as a sweetener is provided for preventing and treating arteriosclerosis, hyperlipemia, liver diseases, and glycosemia. CONSTITUTION: Neohesperidin dihydrochalcone(C28H36O15, M.W. 612.60) is obtained by extracting from the rind or outer layer of grapefruit or by chemically changing Naringin, and it is sweeter 1,500 to 2,000 times than sugar per unit weight. Therefore it has been usually used as a sweetener not a medicinal material. The composition containing an effective amount of neohesperidin dihydrochalcone, that is, 0.1 to 500 mg/kg, preferably 1 to 100 mg/kg a day, is orally or topically administrated into a patient and the amount of administration may be variable by patient's age, weight, sex, health, diet, severity of disease, and so on. The composition containing neohesperidin dihydrochalcone may be added into foods and drinks in an amount of 0.01 to 20 wt.%, preferably 0.1 to 5 wt.% of diosmin.
Abstract:
PURPOSE: A pharmaceutical composition and functional food and drink comprising tannin or phenol-type compounds derived from tannin are provided, for treating and preventing hyper lipidemia, arteriosclerosis and a liver disease. CONSTITUTION: The pharmaceutical composition comprises tannin, gallic acid, ellagic acid or their mixture in effective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of tannin, gallic acid, ellagic acid or their mixture. Tannin, gallic acid and ellagic acid reduce the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase), gamma GTP (gamma-glutamyl transpeptidase) and a lipid in blood, and inhibit the damage of a liver cell and the formation of a fatty liver. Also tannin, gallic acid and ellagic acid strongly inhibit the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface.
Abstract:
PURPOSE: A composition containing a jujube extract and a tangerine pericarp extract containing naringin and hesperidin is provided which has an effect on prevention of adult diseases and cancer such as liver diseases, hypertension, arteriosclerosis, hyperlipidemia or the like when administered to animals. CONSTITUTION: This composition comprises a jujube extract and hesperidin, hesperetin, naringin, naringenin or a mixture thereof as flavonoid originated from a tangerine pericarp extract in a weight ratio of 1:0.001 to 1:0.1. For an example, 5kg jujube is extracted with 15L water at 100deg.C for 2hr two times, followed by filtering. The filtrate is then concentrated under reduced pressure to produce 2kg extract. And 500g tangerine is extracted with 5L ethanol at 60deg.C for 5 hr to produce 190g extract. The jujube extract and tangerine pericarp extract can be orally or parenterally administered at a dose of 0.1 to 5g, preferably 0.5 to 1g and 0.1 to 10g, preferably 0.5 to 2g/kg.weight.day respectively.
Abstract:
PURPOSE: A pharmaceutical composition and functional food and drink comprising neohesperid in dihydrochalcone are provided, for treating and preventing hyper lipidemia, arteriosclerosis, a liver disease and hyperglycemia. CONSTITUTION: The pharmaceutical composition comprises neohesperid in dihydrochalcone ineffective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of neohesperid in dihydrochalcone. Neohesperidin dihydrochalcone reduces the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase) and a lipid in blood, inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and inhibits the damage of a liver cell and the formation of a fatty liver. Also neohesperid in dihydrochalcone strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and reduces the concentration of blood sugar.
Abstract:
PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoid compounds are provided, for descending blood sugar. CONSTITUTION: The pharmaceutical composition comprises the bioflavonoid compounds represented by the formula 1 in effective amount; and pharmaceutically acceptable carriers. In the formula 1, R¬1 represents OH, rutinosyl or rhaminosyl group, R¬2 represents H, OH or rutinosyl group, R¬3 represents H or OH group, R¬4 represents OH or method group, and X represents a single bond or a double bond. The functional food comprises 0.01-50 wt%, preferably 0.05-10 wt% of the bioflavonoid compounds. The compounds of the formula 1 descends blood sugar, and therefore can be used for treating or preventing hyperglycemia.
Abstract:
본 발명은 헤스페리딘(hesperidin)을 포함하는 간 질환의 예방 및 치료용 조성물에 관한 것으로, 본 발명의 조성물은 의약용 및 식품용 조성물을 포함한다. 헤스페리딘은 동물에게 투여되었을 때 혈청 GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase) 및 γGTP(γ-glutamyl transpeptidase)의 농도를 강하시키므로 본 발명의 조성물은 각종 간 질환의 예방 및 치료제로서 유용하게 사용될 수 있다.
Abstract:
본 발명은 B형 간염 바이러스 (HBV)의 표면항원 프리-S1 (pre-S1)에 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 그의 제조방법에 관한 것이다. 구체적으로, 본 발명은 HBV 표면항원 프리-S1 의 21-28번 아미노산을 포함하는 에피토프를 특이적으로 인식하는 생쥐 단일클론항체에 관한 것으로서, 이는 여러 아형 및 변이 HBV 를 중화시킬 수 있어 HBV 감염을 예방하고 치료하는데 널리 사용될 수 있다.
Abstract:
본 발명은 디오스민(diosmin)을 포함하는 동맥경화증 및 고지혈증의 예방 및 치료용 조성물에 관한 것으로, 디오스민은 동물에게 투여되었을 때 동맥내피에 대식세포-지질 복합체가 침착되는 것을 강력히 억제할 뿐만 아니라, ACAT 및 HMG-CoA 환원효소의 활성을 억제하고, 혈중 콜레스테롤 및 중성지질의 농도를 감소시키므로, 동맥경화증 및 고지혈증의 예방 및 치료제로서 유용하게 사용될 수 있다.
Abstract:
PURPOSE: A composition containing the extract of jujube and the extract of citrus rind is provided for improving lipid metabolism and lowering blood pressure, so that it can prevent liver diseases, hypertension, arteriosclerosis, hyperlipemia and cancer. CONSTITUTION: The composition contains 0.1 to 5g/weight kg/day of the extract of jujube and 0.1 to 10g/weight kg/day of the extract of citrus rind in a weight ratio of 1:1 to 100:1, in which the extract of jujube is produced by adding 2 to 5 liter of 70 to 95% ethanol into 1 kg of jujube, and extracting them at 50 to 60deg.C for 1 to 24 hours, or by adding 2 to 5 liter of water into 1 kg of citrus rind, and extracting them at 70 to 121deg.C for 30 minutes to 12 hours; the extract of citrus rind is produced by drying citrus rind, adding 3 to 30 liter of 20 to 95% ethanol into 1kg of dried rind, extracting them at 25 to 80deg.C for 1 to 12 hours, filtering the extract, and condensing it under reduced pressure, wherein citrus includes orange, lemon, tangerine, grapefruit or citron.